Cyclacel Pharmaceuticals Inc

NASDAQ:CYCCUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.

Contact Information

Headquarters

200 Connell Dr Ste 1500BERKELEY HEIGHTS, NJ, United States 07922-2811

Phone

908-517-7330

Fax

866-271-3466

Executives

Independent Chairman of the Board

Christopher Henney

President, Chief Executive Officer, Director

Spiro Rombotis

Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director

Paul Mcbarron

Interim Chief Medical Officer, Director

Brian Schwartz

Independent Director

Samuel Barker